Syndicated News

This blog is still in BETA

We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.

April 06, 2015

Catalyst Bio regains ownership of hemophilia product candidate - Seeking Alpha

April 06, 2015/

http://ift.tt/1yP8adJ Click to read full article...

Catalyst Bio regains ownership of hemophilia product candidateSeeking AlphaFollowing to its previously announced merger with Targacept (TRGT -10.9%), Catalyst Biosciences discloses that Pfizer (PFE +0.1%) has terminated its 2009 license agreement with Catalyst for its lead product candidate, CB 813d, for the treatment of ...Targacept (TRGT) Announces Termination of Catalyst/Wyeth Research ...StreetInsider.comall 3 news articles »

from Hemophilia - Google News http://ift.tt/1yP8adJ via IFTTT

Committee of Ten Thousand

ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL

MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989

The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.

Syndicated News

Syndicated News Feed

Catalyst Bio regains ownership of hemophilia product candidate - Seeking Alpha

Committee of Ten Thousand

Quick Links - Sections